Abstract
dc:descriptionCardiovascular disease (CVD) is the prevalent cause of death worldwide and according to the World Health Organization, it is estimated that 17.9 million people die annually from CVDs, which accounts for the 32% of global mortality. CVDs are the most common noncommunicable disease and describe numerous conditions relating to the heart and blood vessel function and morphogenesis. Coronary artery disease (CAD) is the main CVD implication and is developed when inadequate supply of oxygen and nutrients reach the heart through the coronary artery network. The burden of CVDs along with other noncommunicable diseases (such as cancer, diabetes and chronic pulmonary disease) is expected to further increase due to the aging population and lifestyle patterns. Therefore, it is tremendous need to frame CVDs prognosis, prevention, progression and therapy within the spectrum of modifiable and non-modifiable risk factors. It is well known, that the manifestation of CAD is related with risk factors that can be addressed as behavioral/environmental and genetic effectors. Traditional environmental risk factors include hypertension, dyslipidemia, hyperglycemia, obesity and lifestyle behaviors (smoking, lack of physical activity, poor diet, anxiety and stress-related conditions). In addition to that, it is long recognized that CAD is a heritage disease and plethora of human population studies have aimed to unravel the genetic architecture that underlines the basis of the heart disease. The increase of sample size and genome wide association studies (GWAS) have revealed several susceptibility loci for this multifactorial complex disease. Up to date, there have been identified more than 60 genetic loci correlated with traits of CADs. Such variants associated with the appearance of cardiovascular disease are located to the candidate genes: craniofacial development protein 1 (CFDP1) and coiled-coil domain containing 92 (CCDC92). The aim of this dissertation was to investigate the functional role of CFDP1 and CCDC92 in the cardiac development. For this purpose, we utilized zebrafish (Danio rerio), a valuable model organism in Cardiovascular Research due to the high genomic homology, similarity in heart physiology and the ease of experimental manipulation. CFDP1 belongs to the evolutionary conserved Bucentaur (BCNT) family and up to date, the mechanism of action in cardiovascular development remains unclear. During this dissertation, we generated a cfdp1-null zebrafish line using CRISPR-Cas9 system and identified that the mutated allele carries a pre-mature stop codon at the third exon that produces a predicted truncated protein product. cfdp1 loss leads to a lethal phenotype since knockout individuals do not reach adulthood. Phenotypic characterization showed that cfdp1 knockout embryos develop arrhythmic hearts and defective cardiac performance including statistically significant differences in End Diastolic Volume, Cardiac Output, Ejection Fraction and Stroke Volume. Further analysis in cellular level exhibited that myocardial trabeculation is also impaired in cfdp1 knockout embryonic hearts, suggesting its regulatory role in this essential cardiac developmental process. Finally, conduction of both knockdown and knockout experiments showed that abrogation of cfdp1 results in downregulation of Wnt signaling in embryonic hearts during valve development but without affecting Notch activation in this process. CCDC92 belongs to the superfamily of coiled-coil proteins and although a numerous of variants have been identified in human cardiac conditions, its function is still largely unknown. We showed that zebrafish ccdc92 is expressed during the embryonic development, suggesting its important role in proper organogenesis and function. Following, we performed knockdown experiments by silencing the expression of ccdc92 at one-cell stage zebrafish embryos. Phenotypic characterization of knockdown embryos revealed that deficiency of ccdc92 exhibits embryonic cardiac oedema and heart malformation. Further analysis showed that ccdc92 abrogation results in impaired cardiac looping during embryonic heart morphogenesis, an essential process for the proper structure and function of the heart. More studies are needed to be conducted in order to unravel the mechanism and possible signaling pathways that explain its role in proper cardiac morphogenesis. Protein Kinase D2 belongs to a family of evolutionarily conserved enzymes regulating several biological processes. In a forward genetic screen for zebrafish cardiovascular mutants, it was identified a mutation in the prkd2 gene (T757A substitution) which resulted in a complete outflow tract stenosis. In this study, we showed ectopic expression of Notch-activated cells throughout the heart of mutant embryos as well as higher sensitivity to Cyclosporin A (a Calcineurin inhibitor). Finally, we identify TBX5 as a potential regulator of PRKD2. Our results implicate PRKD2 catalytic activity in outflow tract development in zebrafish. Finally, we participated in the Greek Recurrent Myocardial Infarction Cohort (GRMIC), which is a prospective epidemiologic study that aims to the stratification of post myocardial infarction (MI) patients by integrating genetic and epigenetic predictors together with biomarkers in a risk prediction model. Up to this stage of the study, sixty-six Greek patients have been recruited at the period of first MI event and re-examined after a six months period. Although the sample size remains small, we analyzed the plasma levels of known biomarkers in patients compared to the two time periods and showed that total cholesterol, low-density lipoprotein cholesterol, apolipoprotein-B, C-reactive protein and creatine phosphokinase are significantly higher at the time of first MI event, confirming their prognostic value for the occurrence of first acute MI event. Taking into account that the design of this study requires the recruitment of 500 re-examined MI patients, our data thus far, represent a premature indication of essential biomarkers for MI. GRMIC is an ongoing prospective study that aims to leverage the power of genetics and biomarkers to design risk models for the post-MI patients, in following future.
Degree
thesis:*- Grantor dc:publisher
- Harokopio University
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Giardoglou, Panagiota
- Γιαρδόγλου, Παναγιώτα
Subjects
dc:subject × 18- Καρδιαγγειακά νοσήματα
- Zebrafish
- Τροποποίηση γονιδιώματος βασισμένη στην τεχνολογία CRISPR/Cas9
- cfdp1, ccdc92, prkd2
- Cardiovascular disease
- CRISPR/Cas9 based genome editing
- Βιολογία
- Φυσικές Επιστήμες
- Αναπτυξιακή βιολογία
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες υγείας, άλλοι τομείς
- Biological Sciences
- Natural Sciences
- Developmental Biology
- Health Sciences
- Medical and Health Sciences
- Health sciences, miscellaneous
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51755